<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556292</url>
  </required_header>
  <id_info>
    <org_study_id>QF-SC10914-203</org_study_id>
    <nct_id>NCT04556292</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients</brief_title>
  <official_title>A Phase 2, Open-Label, Multi-Center Study of SC10914 in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received More Than 2 Prior Chemotherapy Regimens for Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, multi-centre phase II study will assess the efficacy and safety of single&#xD;
      agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed up to a maximum of 30 months</time_frame>
    <description>Using Independent Central Review Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Assessed up to a maximum of 30 months</time_frame>
    <description>Using Independent Central Review According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed up to a maximum of 30 months</time_frame>
    <description>from eligible until death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <condition>BRCA 1 Gene Mutation</condition>
  <condition>BRCA 2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>SC10914 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC10914</intervention_name>
    <description>SC10914 400mg tid</description>
    <arm_group_label>SC10914 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Germline mutation in BRCA1 or BRCA2&#xD;
&#xD;
          2. Histologically or cytologically confirmed breast cancer with evidence of metastatic&#xD;
             disease.&#xD;
&#xD;
          3. Prior therapy with an anthracycline and/or a taxane in either an adjuvant or&#xD;
             metastatic setting&#xD;
&#xD;
          4. Patients who have received platinum (cisplatin or carboplatin, either as monotherapy&#xD;
             or in combination) for advanced breast cancer are eligible to enter the study provided&#xD;
             platinum-free interval at least 6 months (time from last dose of platinum chemotherapy&#xD;
             to disease progression&#xD;
&#xD;
          5. Patients who have received platinum as potentially curative treatment for a prior&#xD;
             cancer (e.g. ovarian cancer) or as adjuvant/neoadjuvant treatment for breast cancer&#xD;
             are eligible provided at least 12 months have elapsed between the last dose of&#xD;
             platinum-based treatment and eligible .&#xD;
&#xD;
          6. Patients with estrogen and/or progesterone receptor-positive disease must have&#xD;
             received and progressed on at least one endocrine therapy (adjuvant or metastatic), or&#xD;
             have disease that the treating physician believes to be inappropriate for endocrine&#xD;
             therapy .&#xD;
&#xD;
          7. At least one lesion (measurable and/or non-measurable) that can be accurately assessed&#xD;
             at baseline by CT (MRI where CT is contraindicated) and is suitable for repeated&#xD;
             assessment as per RECIST 1.1.&#xD;
&#xD;
          8. ECOG performance status 0-1.&#xD;
&#xD;
          9. Adequate bone marrow, kidney and liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with PARP inhibitor.&#xD;
&#xD;
          2. Patients with HER2 positive disease&#xD;
&#xD;
          3. Untreated and/or uncontrolled brain metastases&#xD;
&#xD;
          4. Known HIV (Human Immunodeficiency Virus) infection.&#xD;
&#xD;
          5. Persistent toxicities (â‰¥CTCAE grade 2) caused by previous cancer therapy, excluding&#xD;
             alopecia&#xD;
&#xD;
          6. Pregnant or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hu xichun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhang qingsheng, MD,PhD</last_name>
    <phone>13913886090</phone>
    <email>zhangqinsheng@sh-qingfeng.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wu han, MD</last_name>
    <phone>13770507990</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hu xichun, MD</last_name>
      <phone>13811999030</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

